The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
A potent cell-permeable and bivalent Smac mimetic which binds to XIAP, cIAP-1 and cIAP-2 proteins (Ki = 0.56 nM, 0.31 nM and 1.1 nM, respectively). It induces apoptosis and tumor regression in cancer xenograft models.
[TNF protein co-treated with SM 164] results in increased cleavage of BID protein; benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [[TNF protein co-treated with SM 164] results in increased cleavage of BID protein]
SM 164 results in increased cleavage of CASP3 protein [TNF protein co-treated with SM 164] results in increased cleavage of CASP3 protein; benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [[TNF protein co-treated with SM 164] results in increased cleavage of CASP3 protein]
[TNF protein co-treated with SM 164] results in increased cleavage of CASP9 protein; benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [[TNF protein co-treated with SM 164] results in increased cleavage of CASP9 protein]
[SM 164 co-treated with bosutinib] results in decreased expression of CCND1 protein; [SM 164 co-treated with GSK 1363089] results in decreased expression of CCND1 protein
LRIG1 protein affects the susceptibility to SM 164 LRIG1 protein promotes the reaction [SM 164 results in increased expression of TNF mRNA]; LRIG1 protein promotes the reaction [SM 164 results in increased expression of TNF protein]
[ZFP91 protein co-treated with benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone co-treated with SM 164 co-treated with TNF protein] results in increased phosphorylation of MLKL protein [TNF protein co-treated with SM 164 co-treated with benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone] results in increased phosphorylation of MLKL protein
[TNF protein co-treated with SM 164] results in increased cleavage of PARP1 protein; benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [[TNF protein co-treated with SM 164] results in increased cleavage of PARP1 protein]
[ZFP91 protein co-treated with benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone co-treated with SM 164 co-treated with TNF protein] results in increased phosphorylation of RIPK1 protein [benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone co-treated with SM 164 co-treated with TNF protein] results in increased phosphorylation of RIPK1 protein; necrostatin-1 inhibits the reaction [ZFP91 protein promotes the reaction [[benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone co-treated with SM 164 co-treated with TNF protein] results in increased phosphorylation of RIPK1 protein]]; ZFP91 protein promotes the reaction [[benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone co-treated with SM 164 co-treated with TNF protein] results in increased phosphorylation of RIPK1 protein]
[TNF protein co-treated with SM 164 co-treated with benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone] results in increased expression of RIPK3 protein modified form; [ZFP91 protein co-treated with benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone co-treated with SM 164 co-treated with TNF protein] results in increased phosphorylation of RIPK3 protein [benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone co-treated with SM 164 co-treated with TNF protein] results in increased phosphorylation of RIPK3 protein; necrostatin-1 inhibits the reaction [ZFP91 protein promotes the reaction [[benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone co-treated with SM 164 co-treated with TNF protein] results in increased phosphorylation of RIPK3 protein]]; ZFP91 protein promotes the reaction [[benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone co-treated with SM 164 co-treated with TNF protein] results in increased phosphorylation of RIPK3 protein]
[benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone co-treated with SM 164 co-treated with TNF protein] results in increased phosphorylation of RIPK1 protein; [benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone co-treated with SM 164 co-treated with TNF protein] results in increased phosphorylation of RIPK3 protein; [ZFP91 protein co-treated with benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone co-treated with SM 164 co-treated with TNF protein] results in increased phosphorylation of MLKL protein; necrostatin-1 inhibits the reaction [ZFP91 protein promotes the reaction [[benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone co-treated with SM 164 co-treated with TNF protein] results in increased phosphorylation of RIPK1 protein]]; necrostatin-1 inhibits the reaction [ZFP91 protein promotes the reaction [[benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone co-treated with SM 164 co-treated with TNF protein] results in increased phosphorylation of RIPK3 protein]]; ZFP91 protein promotes the reaction [[benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone co-treated with SM 164 co-treated with TNF protein] results in increased phosphorylation of RIPK1 protein]; ZFP91 protein promotes the reaction [[benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone co-treated with SM 164 co-treated with TNF protein] results in increased phosphorylation of RIPK3 protein] SM 164 results in increased expression of TNF mRNA; SM 164 results in increased expression of TNF protein [TNF protein co-treated with SM 164 co-treated with benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone] results in increased expression of RIPK3 protein modified form; [TNF protein co-treated with SM 164 co-treated with benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone] results in increased phosphorylation of MLKL protein; [TNF protein co-treated with SM 164] results in increased cleavage of BID protein; [TNF protein co-treated with SM 164] results in increased cleavage of CASP3 protein; [TNF protein co-treated with SM 164] results in increased cleavage of CASP9 protein; [TNF protein co-treated with SM 164] results in increased cleavage of PARP1 protein; [ZFP91 protein co-treated with benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone co-treated with SM 164 co-treated with TNF protein] results in increased phosphorylation of RIPK1 protein; [ZFP91 protein co-treated with benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone co-treated with SM 164 co-treated with TNF protein] results in increased phosphorylation of RIPK3 protein; benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [[TNF protein co-treated with SM 164] results in increased cleavage of BID protein]; benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [[TNF protein co-treated with SM 164] results in increased cleavage of CASP3 protein]; benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [[TNF protein co-treated with SM 164] results in increased cleavage of CASP9 protein]; benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [[TNF protein co-treated with SM 164] results in increased cleavage of PARP1 protein]; Cycloheximide inhibits the reaction [SM 164 results in increased expression of TNF mRNA]; LRIG1 protein promotes the reaction [SM 164 results in increased expression of TNF mRNA]; LRIG1 protein promotes the reaction [SM 164 results in increased expression of TNF protein]; RELA protein promotes the reaction [SM 164 results in increased expression of TNF mRNA] TNF protein results in increased susceptibility to SM 164
[ZFP91 protein co-treated with benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone co-treated with SM 164 co-treated with TNF protein] results in increased phosphorylation of RIPK1 protein; [ZFP91 protein co-treated with benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone co-treated with SM 164 co-treated with TNF protein] results in increased phosphorylation of RIPK3 protein [ZFP91 protein co-treated with benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone co-treated with SM 164 co-treated with TNF protein] results in increased phosphorylation of MLKL protein; necrostatin-1 inhibits the reaction [ZFP91 protein promotes the reaction [[benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone co-treated with SM 164 co-treated with TNF protein] results in increased phosphorylation of RIPK1 protein]]; necrostatin-1 inhibits the reaction [ZFP91 protein promotes the reaction [[benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone co-treated with SM 164 co-treated with TNF protein] results in increased phosphorylation of RIPK3 protein]]; ZFP91 protein promotes the reaction [[benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone co-treated with SM 164 co-treated with TNF protein] results in increased phosphorylation of RIPK1 protein]; ZFP91 protein promotes the reaction [[benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone co-treated with SM 164 co-treated with TNF protein] results in increased phosphorylation of RIPK3 protein]
browse the term
